Revolution Medicines (RVMD) Interest Expenses (2019 - 2026)

Revolution Medicines' Interest Expenses history runs 8 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• In Q1 2026, Interest Expenses rose 584.85% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (up 584.85% YoY), while the FY2025 annual figure was $885.5 million, up 220.44% from the prior year.
• Interest Expenses for Q1 2026 stood at $1.2 billion, up from -$12.3 million in the prior quarter.
• The five-year high for Interest Expenses was $1.2 billion in Q1 2026, with the low at -$12.3 million in Q4 2025.
• The 5-year median for Interest Expenses is $108.7 million (2023), against an average of $194.5 million.
• The sharpest annual moves came in 2023 and 2025: Interest Expenses jumped 13257.14% in 2023, then tumbled 336.38% in 2025.
• Revolution Medicines' Interest Expenses stood at -$1.4 million in 2022, then surged by 13257.14% to $184.2 million in 2023, then plunged by 101.52% to -$2.8 million in 2024, then sank by 336.38% to -$12.3 million in 2025, then surged by 9636.02% to $1.2 billion in 2026.
• Business Quant data shows RVMD's Interest Expenses at $1.2 billion in Q1 2026, -$12.3 million in Q4 2025, and $328.1 million in Q3 2025.